Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ozanimod · Zeposia 7-Day Starter Pack, RPC-1063

Small molecule · Modulator of S1P receptor 1 (S1PR1) and S1P receptor 5 (S1PR5) · developed by Bristol

Approved FDA, Mar 2020

BMY Developer

2 Registered trials

What is Ozanimod?

Ozanimod is a sphingosine 1-phosphate receptor modulator that binds S1P receptors 1 and 5 with high affinity. It blocks lymphocyte egress from lymph nodes, reducing peripheral lymphocyte numbers and their migration into the central nervous system and intestine.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Zeposia 7-Day Starter Pack, RPC-1063
Drug type: Small molecule
Targets: S1P receptor 1 (S1PR1), S1P receptor 5 (S1PR5)
Mechanism: Modulator of S1P receptor 1 (S1PR1) and S1P receptor 5 (S1PR5)
Pathways: lymphocyte sequestration, lymphocyte migration
Therapy area: Gastroenterology, Neurology
Developer: Bristol (BMY)
Also in trials of: BIIB
FDA status: Approved as Zeposia 7-Day Starter Pack (March 25, 2020), NDA209899 · FDA label
UNII: Z80293URPV

✅ FDA-approved uses

Relapsing forms of multiple sclerosis
Moderately to severely active ulcerative colitis

From the indications section of the FDA label (version of Apr 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05076175	Phase 2/3	Colitis, Ulcerative	Recruiting	BMY
NCT05688436	N/A	Multiple Sclerosis	Active not recruiting	BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colitis, UlcerativeMultiple Sclerosis

Other drugs acting on S1PR1 / S1PR5

Ponesimod FDA approved

More from Bristol

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Ozanimod

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z